Cytokinetics, Incorporated research snapshot
CYTK AI stock analysis currently reads Cytokinetics, Incorporated as a specialty cardiovascular biotech executing a global MYQORZO (aficamten) launch for symptomatic obstructive hypertrophic cardiomyopathy, with UK approval and NICE guidance added in July 2026, while remaining unprofitable and competing with Bristol Myers Squibb Camzyos. At the August 3, 2026 data cutoff, CYTK referenced the July 31, 2026 close near $77.13 with a verified market capitalization of about $10.47 billion on 135.77 million shares. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$77.13
Market cap
$10.47 billion
AI score
59 / 100
Rating
Expanding global commercial HCM biotech, execution and label-event driven
Trend status
Technical trend turned corrective after a large 2026 gain, with price below 20-day and 60-day averages but above the 200-day average; fundamentals still launch-stage and loss-making
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Cytokinetics sells and partners cardiac myosin medicines. MYQORZO is the first fully commercial product for oHCM, launched in the U.S. in January 2026, approved in Europe and China, authorized in the UK, with pipeline options in nHCM, heart failure with reduced ejection fraction (omecamtiv mecarbil), and HFpEF (ulacamten). | High |
| Moat | Moat candidates are cardiac myosin IP, clinical evidence, specialist cardiology relationships, REMS infrastructure, and manufacturing know-how. Competitive intensity versus Camzyos and future labels still tests durability. | Medium |
| Management | Robert I. Blum and team advanced aficamten from late-stage trials through multi-region approvals and a U.S., EU, and UK launch path while raising capital. Ongoing tests are commercial execution, spend control, and capital allocation under high burn. | Medium-high |
| Financial trend | FY2025 revenue was $88.04 million, FY2025 net loss was $784.96 million, and Q1 2026 added $4.8 million of MYQORZO net product revenue in a partial quarter alongside a $206.0 million net loss. Trailing twelve month revenue reached $105.82 million with a net loss of $829.61 million. | High |
| Valuation | At $77.13, CYTK traded near -11.3x trailing EPS of -$6.84 and about 99x trailing revenue per share. PE and PB are not useful quality screens while losses and a stockholders deficit persist, so scenarios rest on launch, label expansion, and future earnings power. | Medium |
| Technical trend | Price fell from the $88.31 high to the mid-$70s, now below the 20-day and 60-day averages while holding above the 200-day average, with support near $76.8 to $77.1 and resistance near $83.6 to $87.2. | Medium |
| Risk level | Main risks are MYQORZO adoption versus Camzyos, REMS and payer access, nHCM regulatory outcomes, high R&D and SG&A burn, convertible and royalty-linked liabilities, dilution, clinical setbacks, and binary events such as the August 6, 2026 Q2 results and the August ESC presentations. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech launch, upcoming earnings, and binary regulatory news can move CYTK faster than static models update. | High data confidence |
| Investment certainty | Medium-low certainty. Commercial traction, the UK approval, and positive ACACIA-HCM topline support the thesis, but the stock needs sustained product growth and controlled funding to justify the current capitalization after the recent pullback. | Medium-low |
CYTK AI stock forecast
The CYTK AI stock forecast uses scenario ranges around the $77.13 reference and an illustrative three-year profitability proxy because trailing GAAP EPS is still negative. financial_rigor.py three-scenario math with a $2.00 illustrative EPS, growth of 45%/20%/0%, and target PE of 40/25/12 produced about $244 bullish, $86 base, and $24 bearish. Those tool outputs are research bounds, not promises. The analyst consensus is Buy with an average 12-month target of $107.80 across 22 analysts as of July 31, 2026.
$200 to $250
More likely if MYQORZO U.S. and EU adoption keeps outpacing Camzyos, the ACACIA-HCM Hot Line at ESC and subsequent FDA discussions expand the label into non-obstructive HCM, operating losses narrow toward sustainable earnings power, and investors keep awarding a premium growth multiple.
$70 to $95
More likely if MYQORZO gains a meaningful but shared oHCM franchise, nHCM progress is gradual, 2026 combined R&D and SG&A stays near the $830 million to $870 million guidance band, Q2 results in August land in line, and valuation stays close to the current commercial-transition multiple.
$20 to $35
More likely if launch demand stalls, Camzyos or other therapies limit share, payer or REMS friction slows paid scripts, nHCM or pipeline data disappoint, cash burn forces more dilution, or the market re-rates CYTK toward a distressed development multiple after a technical breakdown.
CYTK AI technical analysis
CYTK AI technical analysis turned corrective as of the August 3, 2026 cutoff. Company IR and market quotes put the July 31, 2026 close near $77.13, down from the 52-week high near $88.31. Third-party technical sources showed price below the 20-day and 60-day averages but above the 200-day average, with support near $76.8 to $77.1, secondary support near $73.4, and resistance near $83.6 to $87.2. Intellectia labeled the setup Strong Sell on July 31 while StockInvest classified the stock as a Sell candidate since July 28, 2026.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $77.13 | July 31, 2026 close from StockAnalysis market data and StockInvest, down 4.09% on the day from $80.42, used for August 3 research and market cap math. |
| Near support | $76.8 to $77.1 | Intellectia listed S1 support near $76.77 and StockInvest accumulated-volume support near $77.09, close to the July 31 low of $76.96. |
| Secondary support | $73.4 to $76.1 | Intellectia listed S2 near $73.43 with a Fibonacci support near $76.05; StockInvest Fibonacci support clustered near $74.48 to $75.94 if the $77 area fails. |
| Moving averages | Mixed stack | Price held above MA_200 near $67.93 and MA_250 near $63.65 but traded below MA_20 near $81.77 and MA_60 near $78.13 as of July 31, 2026. |
| Resistance | $79.8 to $81.8 | StockInvest flagged moving-average resistance near $79.81 to $80.74 and Intellectia MA_20 near $81.77; a recovery above these would need volume confirmation. |
| Higher resistance | $83.6 to $87.2 | Intellectia listed R1 near $83.64 and R2 near $87.17, with StockInvest accumulated-volume resistance near $82.19 to $87.26; the 52-week high near $88.31 remains the ceiling reference. |
| Momentum | Neutral to negative | RSI near 41.16 was neutral, MACD at -0.146 flashed a sell, while Stochastic near 14.6 and CCI near -131 flashed oversold buy signals, so short-term momentum is weak after the July pullback. |
| Volume | Moderate with recent decline | About 1.58 million shares traded on July 31 versus a 20-day average near 1.72 million; use above-average volume to confirm any breakout or breakdown. |
| Volatility | Event-driven biotech | Clinical, regulatory, earnings, launch, and financing headlines can produce gaps larger than ordinary technical noise; the July 31 daily swing was about 4.97%. |
| Invalidation | Decisive close below $73.4 support | For a trend-following framework, a confirmed break under the $73.4 secondary support after failing at resistance would challenge the corrective structure. It is not a personal sell instruction. |
CYTK AI trading strategy
The CYTK AI trading strategy is a rules-based research framework, not personalized advice. It combines live price confirmation with MYQORZO prescriptions and paid-script trends, competition versus Camzyos, cash burn, debt and royalty obligations, share count after financings, the August 6 Q2 earnings date, FDA calendars, ESC presentations, and EU and UK launch progress.
Wait for CYTK to reclaim the 20-day and 60-day averages near $78 to $82 and for any advance beyond the $83.6 to $87.2 resistance band to show volume confirmation with an unchanged commercial or pipeline thesis. Check the August 6 Q2 results and ESC calendar before relying on a chart pattern.
Define risk before entry. A failed recovery or decisive close below the $73.4 support zone can invalidate this setup.
If CYTK holds the $76.8 to $77.1 support or extends toward the $73.4 secondary band without a negative commercial, clinical, regulatory, earnings, or financing update, wait for stabilization and compare the move with MYQORZO paid prescriptions, cash, liabilities, and program timelines.
Do not average down because a share price fell. The setup fails if support breaks alongside weaker demand, adverse data, delayed label expansion, or a higher funding requirement.
Track MYQORZO net product revenue, REMS-certified HCPs, unique prescribers, paid-script mix, EU and UK launch progress, the MAPLE-HCM PDUFA date of November 14, 2026, ACACIA-HCM full data at ESC, combined R&D and SG&A versus guidance, cash and investments, convertible notes, term loan, royalty-linked liabilities, diluted shares, and competitor HCM data.
Refresh all scenarios after the August 6 Q2 results, ESC presentations, an FDA decision, a financing or royalty transaction, a safety signal, or a large price gap. Avoid stale technical levels around binary events.
Investment research summary
Customers and partners pay Cytokinetics for cardiac muscle medicines and related rights. The core economic question is whether MYQORZO can build a durable global commercial franchise in HCM and whether later myosin programs can broaden the company beyond a single product story.
Relevant protections are patents, myosin biology know-how, clinical data packages, regulatory exclusivity, REMS and specialty distribution infrastructure, and specialist relationships. Those advantages matter only if MYQORZO shows lasting clinical, access, and economic value versus Camzyos and future alternatives.
The thesis can fail if launch growth slows, Camzyos retains most share, REMS or payer barriers limit paid therapy, nHCM approval is delayed or denied, safety or manufacturing issues appear, cash burn forces repeated dilution, or royalty and debt structures constrain flexibility.
Robert I. Blum led the aficamten development and commercial readiness path, including U.S., EU, UK, and China approvals, the January 2026 U.S. launch, the German EU launch, and capital raises such as the May 2026 equity offering. Capital allocation now centers on launch spend, pipeline prioritization, and balance-sheet management under a stockholders deficit.
Targeted therapy for hypertrophic cardiomyopathy and related heart-muscle disease is a multi-year specialty market shaped by diagnosis rates, specialist adoption, REMS complexity, reimbursement, NICE-type access decisions, and head-to-head competitive evidence. Success is discontinuous and news-driven rather than smooth.
The verified $10.47 billion market capitalization prices in substantial MYQORZO success plus pipeline optionality. With trailing EPS of -$6.84, negative book value, and high 2026 expense guidance, margin of safety cannot be read from traditional PE. It requires conservative assumptions about adoption, competition, spend, financing, and label expansion.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CYTK price and market capitalization | $77.13 close on July 31, 2026; $10.47 billion market capitalization; 135.77 million shares outstanding. financial_rigor.py verified price times shares with a 0.02% difference from the $10.47 billion reported market cap. | StockAnalysis market data, cross-checked with StockInvest, verified with financial_rigor.py | August 3, 2026 |
| FY2025 revenue | $88.04 million versus $18.47 million in 2024, up 376.56%. Company IR and StockAnalysis matched within 0.01%. Revenue included collaboration, technology-transfer, and milestone amounts rather than mature product sales. | Cytokinetics Q4 2025 results, cross-checked with StockAnalysis/Fiscal.ai | August 3, 2026 |
| FY2025 net loss | Net loss of $784.96 million, or -$6.54 per share basic and diluted. Company IR and StockAnalysis matched within 0.01%. | Cytokinetics Q4 2025 results, cross-checked with StockAnalysis | August 3, 2026 |
| Q1 2026 revenue, product sales, and net loss | Total revenue $19.4 million, including $4.8 million MYQORZO net product revenue for about 9 weeks of U.S. sales, $2.6 million collaboration revenue, and an $11.9 million Bayer milestone; net loss $206.0 million, or -$1.67 per share. | Cytokinetics Q1 2026 results (May 5, 2026) | August 3, 2026 |
| Trailing twelve month financials | TTM revenue of $105.82 million, net loss of $829.61 million, EPS of -$6.84, operating cash flow of -$523.85 million, and free cash flow of -$548.92 million as reported by StockAnalysis. | StockAnalysis statistics page (S&P Global) | August 2, 2026 |
| MYQORZO early U.S. launch metrics (as of March 31, 2026) | Over 1,400 HCPs REMS certified; over 275 unique HCPs prescribed MYQORZO; about 680 patients prescribed; over 70% of patients on therapy on paid prescription. | Cytokinetics Q1 2026 results | August 3, 2026 |
| Cash, cash equivalents and investments | About $1.1 billion at March 31, 2026 per company narrative; balance-sheet cash and short-term investments of $818.6 million plus long-term investments of $254.7 million totaled about $1.07 billion. Cross-validation consensus about $1.08 billion with 1.38% source spread. | Cytokinetics Q1 2026 results and condensed balance sheet | August 3, 2026 |
| Debt and related obligations (March 31, 2026) | Current portion of convertible and long-term debt $44.8 million; term loan net $247.2 million; convertible notes net $870.5 million; revenue participation liabilities net $539.1 million; RPI-related liabilities at fair value $138.8 million. Stockholders deficit about $826.6 million. | Cytokinetics Q1 2026 condensed consolidated balance sheet | August 3, 2026 |
| 2026 expense guidance and May 2026 equity financing | GAAP combined R&D and SG&A guidance $830 million to $870 million. May 2026 public offering of 9,859,155 shares at $71.00 for about $700 million gross proceeds before fees, plus underwriter option for 1,478,873 shares. | Cytokinetics Q1 2026 results and May 6, 2026 offering pricing release | August 3, 2026 |
| Regulatory, launch, and pipeline calendar | EC approval with first EU launch in Germany on June 1, 2026; MHRA marketing authorisation in the UK and positive NICE guidance on July 30, 2026; ACACIA-HCM nHCM topline positive on dual primary endpoints with full results in a Hot Line at ESC Congress August 28 to 31, 2026; MAPLE-HCM sNDA PDUFA date November 14, 2026; Swissmedic application submitted; omecamtiv mecarbil COMET-HF and ulacamten AMBER-HFpEF ongoing. | Cytokinetics IR press releases: Q1 2026 results, MHRA/NICE, EU Germany launch, and ESC abstracts | August 3, 2026 |
| Analyst consensus and estimates | Buy consensus across 22 analysts with an average price target of $107.80 (range $83 to $146) as of July 31, 2026. Consensus FY2026 revenue about $112.9 million with EPS near -$6.31, and FY2027 revenue about $393.4 million with EPS near -$4.69. | StockAnalysis forecast page (S&P Global and TipRanks) | August 3, 2026 |
| Technical snapshot | Price below MA_20 ~$81.77 and MA_60 ~$78.13, above MA_200 ~$67.93 and MA_250 ~$63.65; RSI 41.16; support near $76.77 to $77.09 with secondary support near $73.43; resistance near $83.64 to $87.17; 52-week range about $32.89 to $88.31; short interest about 17.05 million shares (12.56% of shares out). | Intellectia technical page and StockAnalysis statistics | August 3, 2026 |
| Valuation and scenario tool checks | financial_rigor.py PE about -11.3x on trailing EPS -$6.84 and PS about 98.96x on revenue per share of $0.78; three-scenario illustrative path with $2.00 EPS proxy, growth 45%/20%/0%, and PE 40/25/12 produced about $244 / $86 / $24 over three years. | financial_rigor.py verify-valuation and three-scenario | August 3, 2026 |
This CYTK page is an informational research tool, not investment advice, a recommendation, or a guarantee of performance. Forecast ranges are scenarios based on available dated data and assumptions that can be wrong. Verify live market data and primary filings before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
